Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MANBA | O00462 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13986503 | 1.00 | LMNA (0.39) | LMNAMANBATHRBHIF1AMAPT | |
| SCHEMBL6276072 | 1.00 | LMNA (0.39) | LMNAMANBATHRBHIF1AMAPT | |
| SCHEMBL13986495 | 0.82 | FKBP1A (0.34) | — | |
| SCHEMBL21481974 | 0.82 | — | — | |
| SCHEMBL22872727 | 0.82 | — | — | |
| SCHEMBL13986492 | 0.82 | FKBP1A (0.34) | — | |
| SCHEMBL13986493 | 0.82 | FKBP1A (0.34) | — | |
| SCHEMBL12261474 | 0.81 | HIF1A (0.37) | LMNAMANBATHRBHIF1A | |
| SCHEMBL7878475 | 0.76 | — | — | |
| SCHEMBL7878311 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2634180-A1 | Enzymatic process for the preparation of butyrolactones | Lonza Ltd. (CH) | 2013-09-04 | — | — | EP | disclosed |
| US-7468448-B2 | Production method of hexahydrofurofuranol derivative, intermediate therefor and production method thereof | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2008-12-23 | — | — | US | disclosed |
| US-7468448-B2 | Production method of hexahydrofurofuranol derivative, intermediate therefor and production method thereof | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2008-12-23 | — | — | US | disclosed |
| US-7468448-B2 | Production method of hexahydrofurofuranol derivative, intermediate therefor and production method thereof | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2008-12-23 | — | — | US | disclosed |
| US-20050256322-A1 | Production method of hexahydrofurofuranol derivative, intermediate therefor and production method thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1589018-A1 | PROCESS FOR PRODUCING HEXAHYDROFUROFURANOL DERIVATIVE, INTERMEDIATE THEREOF AND PROCESS FOR PRODUCING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2005-10-26 | — | — | EP | disclosed |
| US-6867321-B2 | Production method of hexahydrofurofuranol derivative, intermediate therefor and production method thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-03-15 | — | — | US | disclosed |
| US-20040162340-A1 | Production method of hexahydrofurofuranol derivative, intermediate therefor and production method thereof | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256322-A1 | Production method of hexahydrofurofuranol derivative, intermediate therefor and production method thereof | CYP4F11, CYP51A1, CYP4A11 | LMNA 1601/4885MANBA 2322/4885THRB 3795/4885 |
| US-20040162340-A1 | Production method of hexahydrofurofuranol derivative, intermediate therefor and production method thereof | CYP4F11, CYP51A1, CYP4A11 | LMNA 1556/4885MANBA 2355/4885THRB 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.